Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells

Margarita V. Romanenko; Evgeniya V. Dolgova; Ivan D. Osipov; Genrikh S. Ritter; Mariya S. Sizova; Anastasia S. Proskurina; Yaroslav R. Efremov; Sergey I. Bayborodin; Ekaterina A. Potter; Oleg S. Taranov; Vladimir V. Omigov; Galina V. Kochneva; Antonina A. Grazhdantseva; Evgeniy L. Zavyalov; Ivan A. Razumov; Sergey V. Netesov; Sergey S. Bogachev

doi:10.21873/anticanres.13815

Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells

Margarita V. Romanenko, Evgeniya V. Dolgova, Ivan D. Osipov, Genrikh S. Ritter, Mariya S. Sizova, Anastasia S. Proskurina, Yaroslav R. Efremov, Sergey I. Bayborodin, Ekaterina A. Potter, Oleg S. Taranov, Vladimir V. Omigov, Galina V. Kochneva, Antonina A. Grazhdantseva, Evgeniy L. Zavyalov, Ivan A. Razumov, Sergey V. Netesov, Sergey S. Bogachev

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background/Aim: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. Materials and Methods: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. Results: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. Conclusion: Ad6 was shown to be a promising agent for treating glioblastomas.

Original language	English (US)
Pages (from-to)	6073-6086
Number of pages	14
Journal	Anticancer Research
Volume	39
Issue number	11
DOIs	https://doi.org/10.21873/anticanres.13815
State	Published - 2019
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported by the State Project of the Institute of Cytology and Genetics # 0324-2019-0042, State Project #6.5546.2017 of Novosibirsk State University, top-100 Program Funding of the same University and the grant #18-34-20016 of the Russian Foundation for Basic Research.

Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.

Keywords

Cancer stem cells
DNA internalization
TAMRA
U87 cell line
Аdenovirus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.21873/anticanres.13815

OpenUrl availability

Full text

Cite this

Romanenko, M. V., Dolgova, E. V., Osipov, I. D., Ritter, G. S., Sizova, M. S., Proskurina, A. S., Efremov, Y. R., Bayborodin, S. I., Potter, E. A., Taranov, O. S., Omigov, V. V., Kochneva, G. V., Grazhdantseva, A. A., Zavyalov, E. L., Razumov, I. A., Netesov, S. V., & Bogachev, S. S. (2019). Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells. Anticancer Research, 39(11), 6073-6086. https://doi.org/10.21873/anticanres.13815

Romanenko, MV, Dolgova, EV, Osipov, ID, Ritter, GS, Sizova, MS, Proskurina, AS, Efremov, YR, Bayborodin, SI, Potter, EA, Taranov, OS, Omigov, VV, Kochneva, GV, Grazhdantseva, AA, Zavyalov, EL, Razumov, IA, Netesov, SV & Bogachev, SS 2019, 'Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells', Anticancer Research, vol. 39, no. 11, pp. 6073-6086. https://doi.org/10.21873/anticanres.13815

@article{c430d836cd2d461ab72994978d822dea,

title = "Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells",

abstract = "Background/Aim: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. Materials and Methods: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. Results: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. Conclusion: Ad6 was shown to be a promising agent for treating glioblastomas.",

keywords = "Cancer stem cells, DNA internalization, TAMRA, U87 cell line, Аdenovirus",

author = "Romanenko, {Margarita V.} and Dolgova, {Evgeniya V.} and Osipov, {Ivan D.} and Ritter, {Genrikh S.} and Sizova, {Mariya S.} and Proskurina, {Anastasia S.} and Efremov, {Yaroslav R.} and Bayborodin, {Sergey I.} and Potter, {Ekaterina A.} and Taranov, {Oleg S.} and Omigov, {Vladimir V.} and Kochneva, {Galina V.} and Grazhdantseva, {Antonina A.} and Zavyalov, {Evgeniy L.} and Razumov, {Ivan A.} and Netesov, {Sergey V.} and Bogachev, {Sergey S.}",

note = "Funding Information: This study was supported by the State Project of the Institute of Cytology and Genetics # 0324-2019-0042, State Project #6.5546.2017 of Novosibirsk State University, top-100 Program Funding of the same University and the grant #18-34-20016 of the Russian Foundation for Basic Research. Publisher Copyright: {\textcopyright} 2019 International Institute of Anticancer Research. All rights reserved.",

year = "2019",

doi = "10.21873/anticanres.13815",

language = "English (US)",

volume = "39",

pages = "6073--6086",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "11",

}

TY - JOUR

T1 - Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells

AU - Romanenko, Margarita V.

AU - Dolgova, Evgeniya V.

AU - Osipov, Ivan D.

AU - Ritter, Genrikh S.

AU - Sizova, Mariya S.

AU - Proskurina, Anastasia S.

AU - Efremov, Yaroslav R.

AU - Bayborodin, Sergey I.

AU - Potter, Ekaterina A.

AU - Taranov, Oleg S.

AU - Omigov, Vladimir V.

AU - Kochneva, Galina V.

AU - Grazhdantseva, Antonina A.

AU - Zavyalov, Evgeniy L.

AU - Razumov, Ivan A.

AU - Netesov, Sergey V.

AU - Bogachev, Sergey S.

N1 - Funding Information: This study was supported by the State Project of the Institute of Cytology and Genetics # 0324-2019-0042, State Project #6.5546.2017 of Novosibirsk State University, top-100 Program Funding of the same University and the grant #18-34-20016 of the Russian Foundation for Basic Research. Publisher Copyright: © 2019 International Institute of Anticancer Research. All rights reserved.

PY - 2019

Y1 - 2019

N2 - Background/Aim: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. Materials and Methods: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. Results: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. Conclusion: Ad6 was shown to be a promising agent for treating glioblastomas.

AB - Background/Aim: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. Materials and Methods: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. Results: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. Conclusion: Ad6 was shown to be a promising agent for treating glioblastomas.

KW - Cancer stem cells

KW - DNA internalization

KW - TAMRA

KW - U87 cell line

KW - Аdenovirus

UR - http://www.scopus.com/inward/record.url?scp=85074717832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074717832&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13815

DO - 10.21873/anticanres.13815

M3 - Article

C2 - 31704835

AN - SCOPUS:85074717832

SN - 0250-7005

VL - 39

SP - 6073

EP - 6086

JO - Anticancer Research

JF - Anticancer Research

IS - 11

ER -

Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this